Introduction {#Sec1}
============

Among heterocyclic pharmacophores, the benzimidazole ring system is quite common. These substructures are often called 'privileged' due to their wide recurrence in bioactive compounds \[[@CR1]\]. Benzimidazole moiety is a fusion of benzene and imidazole ring system at the 4 and 5 positions of imidazole ring. They have properties of both acids and bases. The NH group here is highly acidic and also feebly basic. Another feature of it is that they comprise the ability to form salts. The benzimidazole moiety is useful for the development of novel medicinal compounds in pharmaceutical field. Benzimidazole is also a vital pharmacophore, a privileged sub-structure in medicinal chemistry which contributes as a key part for different natural activities \[[@CR2]\].

Pharmacological significance of benzimidazole derivatives {#Sec2}
---------------------------------------------------------

Literature survey reveals that the various derivatives of benzimidazole have been synthesized for their pharmacological activities such as antimicrobial \[[@CR3]\], anticancer \[[@CR2]\], acetylcholinesterase \[[@CR4]\], antiprotozoal \[[@CR5]\], anti-inflammatory \[[@CR6]\], analgesic \[[@CR7]\], antihistaminic \[[@CR8]\], antimalarial \[[@CR9]\], antitubercular \[[@CR10]\], anti-HIV \[[@CR11]\] and antiviral \[[@CR12]\]. Some of the already synthesized compounds from the above mentioned field have found very strong application in medicine praxis. The activity against bacteria, fungi and helminthes resulted their mode of action, which resulted in the blockage of microtubule in various nematode, trematode and cystode \[[@CR13]\]. Benzimidazole-based drugs exhibit a wide range of different biological activities as a result of changing the groups on the core structure. Some marketed drugs containing benzimidazole nucleus are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Some benzimidazoles containing medicinal preparation

Acetylcholinesterase (AChE) is a core chemical engaged with the ending of nerve signs via the hydrolysis of acetylcholine. It is an objective of medication advancement to battle the neuromuscular issue, for example, glaucoma, myasthenia gravis and Alzheimer's disease (AD). AChE has been focused in the cure of AD, a dynamic neurodegenerative disease portrayed by neurofibrillary tangles, *β*-amyloid plaques and loss of focal cholinergic ability. A lack in cholinergic neurotransmission is viewed as one of the real reasons for reminiscence weaknesses in the patients with AD. One of the compelling methodologies for improving the cholinergic transmission is to utilize the inhibitors of acetylcholinesterase \[[@CR4]\]. Parasitic ailments are as yet overall issues that deeply affect general wellbeing. Contaminations brought about by protozoa, for example, *Trypanosoma cruzi*, *Plasmodium falciparum*, *Entamoeba histolytica*, *Leishmania Mexicana*, *Trichomonas vaginalis*, *Giardia intestinalis* and helminth, for example, *Taenia solium* or *Trichinella spiralis* are overall spread ailments that influence predominantly immature nations, where tropical or template temperatures exist, yet in addition poor uncontaminated and cleanliness conditions are normal \[[@CR14]\].

Irritation is a confined reaction of body tissues to destructive incentives or injures bringing about the arrangement of protein-rich exudates. It is a defensive reaction of the nonspecific resistant framework that expels the essential driver of cell damage; eradicate necrotic cells and tissues harmed from the incendiary procedure and commence tissue repair. The essential indications of aggravation are redness, heat, torment, swelling and loss of capacity. Reason for aggravation is physical as well chemical means, immunological responses and contamination by pathogenic life form. Aggravation can be assigned as acute and chronic. Acute irritation is described by the exudation of liquid and plasma proteins (oedema) and the development of leukocytes, particularly neutrophils. Chronic irritation is otherwise called constant aggravation, in which tissue destruction and recovering are continuing all the while, for example, tuberculosis, rheumatoid joint inflammation, constant lung infections and atherosclerosis \[[@CR6]\].

Mosquitoes are one of the deadliest creepy crawlies in earth which generate biting irritation and also transmit lethal infections, for example, intestinal sickness, yellow fever, filariasis, chikungunya, encephalitis and dengue. Mosquitoes in the class Aedes are liable for the transmission of chikungunya, dengue, yellow fever and other pathogenic arbo-infections. Likewise, the prime vector for lymphatic filariasis is *Culex quinquefasciatus*, as well called southern house mosquito. *Cx. quinquefasciatus* ordinarily stay around human lodging and on maturing like to nibble people than different warm blooded creatures. Intestinal sickness is a mosquito-borne infectious ailment which is mostly transmitted by a contaminated female Anopheles mosquito \[[@CR15]\].

Tuberculosis (TB), which is caused prevalently by *Mycobacterium tuberculosis* (Mtb), is the main source of death from a reparable irresistible ailment, and has been recognized by the World Health Organization (WHO) as one of the three need illnesses for medication innovative work \[[@CR16]\]. Viral hemorrhagic fever is a genuine sickness portrayed by broad vascular harm and draining diathesis, fever and various organ inclusions. Various infections can cause this disorder, each with its very own creature repository, method of transmission, mortality rate, and clinical result in people \[[@CR17]\].

Worldwide infectious disease figures have attained an alarming level following the proliferation of Gram-positive and Gram-negative multi-drug-resistant species. Patient non-compliance and the occurrence of multidrug-resistant pathogens often interfere innovative infection therapies that depend on a sustained multidrug course. Rational drug design has been shown to be very beneficial in this respect, since the biochemical basis of intrinsic and acquired resistance mechanisms is largely known \[[@CR3]\].

One of the most commonly known gastrointestinal malignancies is colorectal tumor (CRC). Alterations in lifestyle, elevated-fat diet, physiological disillusionment and smoking are associated to pathogenesis of CRC. Approximately 25% of CRC cases were identified with early analysis metastases and at some stage of life nearly 50% of CRC patients would suffer from metastasis. The therapy results for these patients are largely unsatisfactory as normal regimens consider the possibility of homogeneous tumor mass distribution \[[@CR2]\].

Rational designed based on literature survey of benzimidazole derivatives is shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Rational designed based on literature survey of benzimidazole derivatives

Reported pharmacological activities of benzimidazole derivatives {#Sec3}
================================================================

Acetyl cholinesterase inhibitory {#Sec4}
--------------------------------

Alpan et al. designed a class of *N*-{2-\[4-(1*H*-benzimidazole-2-yl)phenoxy\]ethyl} substituted amines and evaluated for its butyrylcholinesterase and acetylcholinesterase inhibitor activity. Among the synthesized derivatives, compounds **1a** and **1b** were found to be the most active against *ee*AChE and *h*AChE using tacrine as standard drug (Table [1](#Tab1){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR4]\].Table 1In vitro inhibition of AChE/BuChE of compounds (**1a** and **1b**)Comp.IC~50~ ± SEM (µM)*ee*AChE*h*AChEBchE**1a**0.58 ± 0.063.68 ± 0.397.44 ± 1.51**1b**0.61 ± 0.070.13 ± 0.03\> 100**Tacrine**0.075 ± 0.020.52 ± 0.090.0098 ± 0.0002 Fig. 3Molecular structures of compounds (**1a**--**1b**, **2a**, **3a**--**3c**, **4a**, **5a**--**5c**, **6a**--**6d**, **7a**--**7b**, **8a**)

Yoon et al. synthesized a class of benzimidazoles and screened for its acetylcholinesterase and butyrylcholinesterase inhibitor activity. Compound **2a** (Fig. [3](#Fig3){ref-type="fig"}) showed promising inhibitory activity with IC~50~ = 5.12 µM for BChE and IC~50~ = 8.63 µM for AChE using rivastigmine and donepezil (22.00, 7.95 µM for BChE and 50.20, 0.03 µM for AChE) as standard \[[@CR18]\].

Antiprotozoal activity {#Sec5}
----------------------

Andrzejewska et al. synthesized two series of *S*-substituted 4,6-dihalogeno-2-mercapto-1*H*-benzimidazoles and assessed for their in vitro antiprotozoal potential towards *G. intestinalis* and *T. vaginalis* using albendazole and metronidazole as standard. Among them, compounds **3a**, **3b** and **3c** were found to be most potent and comparable to standard drugs (Table [2](#Tab2){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR5]\].Table 2Antiprotozoal activity of benzimidazole compounds (**3a**--**3c**)Comp.IC~50~ µg/mL*Giardia intestinalisTrichomonas vaginalis***3a**0.0060.021**3b**0.0060.013**3c**0.0080.004**Albendazole**0.0100.422**Metronidazole**0.2100.037

Diaz-Chiguer et al. prepared a new series of benzimidazole derivatives and evaluated in vitro (via the % of lysis of bloodstream) and in vivo for its trypanocidal activity against of *Trypanosoma cruzi* (NINOA and INC5). In this series, compound **4a** showed significant in vitro and in vivo \[INC5: 68.4 (% lysis); NINOA: 46.4 (% lysis)\] trypanocidal activity (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR19]\].Table 3In vitro trypanocidal activity of synthesized compound **4a**Comp.*Trypanosoma cruzi*LC~50~ (mM)CC~50~ (mM)Selectivity index (SI)INC5NINOAINC5NINOA**4a**0.320.01443.21353085.71**Nifurtimox**0.690.7825.436.8132.56**Benznidazole**0.310.6023.676.1339.3

Hernandez-Covarrubias et al. reported a class of benzimidazoles and evaluated for its antiprotozoal activity against *G. duodenalis*. All the tested compounds were found to be more active than standard metronidazole but the better activity observed with SH group compounds **5a**--**5c** (Fig. [3](#Fig3){ref-type="fig"}) (IC~50~ = 18--45 µM) which exhibited considerable activity as compared to metronidazole (IC~50~ = 1.22 µM) \[[@CR20]\].

Hernandez-Luis et al. synthesized a series of 2-(trifluoromethyl)-1*H*-benzimidazole molecules and assessed in vitro for its antiparasitic activity towards various protozoan parasites: *G. intestinalis* (GI), *T. vaginalis* (TV) *E. histolytica* (EH) and *L. mexicana* (LM) using albendazole (ABZ), mebendazole (MBZ), pentamidine as standard drugs and in vivo towards *Trichinella spiralis* (TS) using albendazole (ABZ), triclabendazole (TBZ) and pentamidine as standard drugs. In this class, compounds **6a**, **6b** and **6c** exhibited good antiparasitic activity and in addition, compound **6a** and **6c** showed good activity against *T. spiralis* at adult phase and **6d** possessed the good antiprotozoal potential against the muscle larvae stage (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR14]\].Table 4In vitro antiprotozoal and anthelmintic screening resultsComp.Microbial strains (IC~50~ µg/mL)GIEHTVLMTS (% reduction, 0.18 µM)TS (% reduction, 0.37 µM)TS (% reduction, 1.80 µM)**6a**0.0300.0090.01624.0054 ± 262 ± 280 ± 3**6b**0.0630.0190.1104.1044 ± 248 ± 367 ± 2**6c**0.0050.0190.08613.7843 ± 350 ± 265 ± 3**ABZ**0.03756.61.592^a^58.6 ± 261.9 ± 367 ± 6**MTZ**1.2280.3500.216^bbbb^**Pentamidine**^bbb^2.421^bbba^No effect^b^Not determined Table 5Percentage of adult and muscle larvae load reduction in *T. spiralis*Comp.Adult phaseMuscle larvae stage50 mg/kg75 mg/kg75 mg/kg**6a**^a^5846**6c**698040**6d**^b^3664**ABZ**627363**MTZ**41725**Alpha**28^a^24**Control**000^a^Not determined^b^No reduction

Kopanska et al. reported a series of 1*H*-benzimidazole analogues and assessed for its in vitro antiprotozoal activity against *Acanthamoeba castellanii* and compared with chlorhexidine as reference. The screening results indicated that compounds **7a** and **7b** were found most efficient in reducing the figure of trophozoites and cysts (Table [6](#Tab6){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR21]\].Table 6Reduction in viability of *A. castellanii* trophozoites and cystsComp.Concentrations \[µmol/L\]% of survivorsPercentage content of particular stagesTrophozoitesCystsTotalTrophozoitesCysts**7a**5.523.3 ± 2.015.0 ± 2.322.5 ± 2.093.4 ± 8.06.6 ± 1.011.141.2 ± 2.876.0 ± 9.744.5 ± 3.583.6 ± 5.716.4 ± 2.1**7b**5.226.5 ± 2.319.0 ± 3.425.8 ± 2.492.7 ± 7.97.3 ± 1.37.922.0 ± 1.8121.0 ± 12.631.6 ± 2.962.5 ± 5.237.5 ± 3.9**Chlorohexidine**4.423.4 ± 0.711.0 ± 1.622.3 ± 0.895.3 ± 2.94.7 ± 0.711.024.2 ± 1.131.0 ± 4.824.8 ± 2.688.4 ± 3.911.6 ± 1.8

Mavrova et al. synthesized novel derivatives of thieno\[2,3-*d*\]pyrimidin-4(3*H*)-ones and screened for their in vitro antiparasitic activity against *Trichinella spiralis* using albendazole (as standard drug). Among them, compound **8a** showed good antiparasitic activity. The significance results of the active compound shown in Table [7](#Tab7){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"} \[[@CR22]\].Table 7Antihelmintic activity of compound 8a against *Trichinella spiralis*Comp.Efficacy (%) after 24 hEfficacy (%) after 48 h**8a**95.0595.05**Albendazole**10.614.8

Navarrete-Vazquez et al. synthesized a sequence of 2-(trifluoromethyl)-1*H*-benzimidazoles along with various bioisosteric substituents at 5- and 6-position (--Cl, --F, --CF~3~, --CN) and examined for its in vitro antiprotozoal activity towards the protozoa *T. vaginalis* and *G. intestinalis* using metronidazole and albendazole as reference. In this series, compound **9a** showed most promising activity than metronidazole against *G. intestinalis* and compound **9b** found more active against *T. vaginalis* than the reference drugs. The compound **9b** as well displayed modest antimalarial activity against D6 and W2 strains of *Plasmodium falciparum* (Table [8](#Tab8){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR23]\].Table 8IC~50~ (μM) of synthesized compounds (**9a** and **9b**)Comp.*G. intestinalisT. vaginalisP. falciparum*D6W2**9a**0.107 ± 0.0173.314 ± 0.130\> 20\> 20**9b**0.672 ± 0.0200.232 ± 0.0215.98 ± 0.256.12 ± 0.32**Metronidazole**1.226 ± 0.1250.236 ± 0.016----**Albendazole**0.038 ± 0.0033.390 ± 0.125\> 20\>20 Fig. 4Molecular structures of compounds (**9a**--**9b**, **10a**--**10c**, **11a**--**11b**, **12a**--**12b**, **13a**, **14a**, **15a**, **16a**--**16b**, **17a**--**17b**, **18a**)

Marquez-Navarro et al. developed new derivatives of benzimidazole moiety and examined for their in vivo antiprotozoal activity toward *Hymenolepis nana* adult and in vitro toward *Toxocara canis* larvae. In vitro screening results indicated that compound **10a** showed significant activity toward *T. canis* whereas compounds **10b** and **10c** showed the good in vivo results against *H. nana* and compared to standard albendazole (Table [9](#Tab9){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR24]\].Table 9Antihelmintic screening resultsComp.C log P*T. canis* J2 larvae in vitro relative mobility (%)*H. nana* in vivo adult reduction (%)0.18 µM1.8 µM18 µM50 mg/kg**10a**3.23404030--**10b**--------97**10c**--------96**Albendazole**3.0180404083

Oh et al. synthesized a novel class of 2,3-dihydroimidazo\[1,2-*a*\]benzimidazole and screened for its anti-leishmanial and anti-trypanosomal activities towards *Leishmania donovani* and *Trypanosoma cruzi* using miltefosine, benznidazole and amphotericin B as standard. Compounds **11a** and **11b** showed promising antiprotozoal activity (Tables [10](#Tab10){ref-type="table"} and [11](#Tab11){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR25]\].Table 10In vitro anti-leishmanial screening resultsComp.*Leishmania donovani*Amastigote formPromastigote formEC~50~ (μM)CC~50~ (μM)SIEC~50~ (μM)**11a**3.05\> 50\> 16.41.25**11b**5.2939.77.51.48**Miltefosine**4.8318.93.9111.1**Amphotericin B**0.257.5730.20.22*CC*~*50*~ cytotoxicity, *EC*~*50*~ half maximal effective concentration, *SI* selective index (EC~50~/CC~50~) Table 11In vitro anti-trypanosomal screening resultsComp.*Trypanosoma cruzi*EC~50~ (μM)CC~50~ (μM)SI**11a**1.1036.533.2**11b**2.1018.88.95**Benznidazole**20.7\> 50\> 2.42

Palomares-Alonso et al. developed new substituted benzimidazoles and assessed for their cysticidal activity against *Taenia crassiceps* cysts (ORF and WFU strain) using albendazole sulfoxide as control drug. Among them, compounds **12a** and **12b** displayed superior cysticidal activity (Table [12](#Tab12){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR26]\].Table 12Cysticidal activity against *T. crassiceps* (ORF and WFU strains)Comp.Cysts mortality (%)ORF strainWFU strain0.28 µM1.70 µM0.28 µM1.70 µM**12a**41 ± 4.668 ± 722.6 ± 2.326 ± 4**12b**37 ± 6.162 ± 86.3 ± 2.316.7 ± 3**Albendazole sulfoxide**46 ± 588 ± 725 ± 2.335 ± 2.3

Perez-Villanueva et al. synthesized a new class of 2-{\[2-(1*H*-imidazol-1-yl)ethyl\]-sulfanyl}-1*H*-benzimidazole derivatives and assessed for its in vitro antiprotozoal activity against protozoa *G. intestinalis, T. vaginalis* and *E. histolytica* using metronidazole and albendazole as standard drugs. Among them, compound **13a** showed highest activity against *G. intestinalis* (Table [13](#Tab13){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR27]\].Table 13Antiprotozoal screening resultsComp.Microbial strains IC~50~ (µM)*T. vaginalisG. intestinalisE. histolytica***13a**0.0761 ± 0.00940.0083 ± 0.00230.0298 ± 0.0047**Meteronidazole**0.2360 ± 0.01601.2260 ± 0.12500.3798 ± 0.1461**Albendazole**1.5905 ± 0.01130.0370 ± 0.003056.5334 ± 18.8445

Sondhi et al. synthesized pyrimido\[1,6-*a*\]benzimidazoles and assessed for their in vitro antiamoebic activity by microdilution method against *E. histolytica*. In this series, compound **14a** (Fig. [4](#Fig4){ref-type="fig"}) showed best IC~50~ value 1.82 µM as compared to metronidazole which showed IC~50~ value 1.22 µM \[[@CR28]\].

Torres-Gomez et al. reported some benzimidazole pentamidine compounds and assessed for their in vitro antiprotozoal activity against *L. Mexicana*, *E. histolytica*, *Giardia lamblia*, *T. vaginalis* and *Plasmodium berghei* using pentamidine and metronidazole (as reference drugs). Among the reported compounds, compound **15a** showed good activity against *G. lamblia*, *E. histolytica, L. mexicana* and *T. vaginalis* and comparable to standard pentamidine (Table [14](#Tab14){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR29]\].Table 14Antiprotozoal screening resultsComp.Microbial strains (IC~50~ µ/M)*T. vaginalisG. lambliaE. histolyticaL. mexicanaP. berghei***15a**0.1640.4350.10934.6410.712**Pentamidine**3.8154.07911.801^a^9.568**Meteronidazole**0.2861.2860.771------ Not tested^a^Cell damage, due to cytophatic effect caused by pentamidine

Velazquez-Lopez et al. reported some new benzimidazole derivatives and evaluated for their in vitro antiprotozoal activity against *T. cruzi* epimastigotes INC-5 and NINOA using reference drug (nifurtimox). Among the synthesized compounds, compound **16a** showed potent activity towards the *T. cruzi* epimastigote INC-5 strain while compound **16b** found active against the NINOA strain and comparable to nifurtimox (Table [15](#Tab15){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR30]\].Table 15In vitro susceptibility of bloodstream epimastigoteComp.IC~50~ INC-5 (μM)IC~50~ NINOA (μM)CC~50~ (μM)**16a**28.672 ± 0.60298.799 ± 1.990134.580 ± 1.995**16b**186.230 ± 4.10356.967 ± 0.96190.436 ± 1.426**Nifurtimox**50.750 ± 0.83989.804 ± 1.138131.503 ± 0.490

Anti-inflammatory activity {#Sec6}
--------------------------

Achar et al. prepared a class of 2-methylaminobenzimidazole compounds and screened in vivo for its analgesic (acetic acid induced writhing in mice) and anti-inflammatory activities (carrageenan induced paw oedema in rats). Among them, compounds **17a** and **17b** were displayed considerable analgesic and anti-inflammatory activities in comparison to reference nimesulide (Tables [16](#Tab16){ref-type="table"}, [17](#Tab17){ref-type="table"} and [18](#Tab18){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR6]\].Table 16Analgesic screening resultsComp.Mean values (X ± SE)(%) Protection**Control**300 ± 1.55--**17a**5.6 ± 1.8581.33**17b**3.3 ± 1.6689.00**Nimesulide**--100 Table 17Anti-inflammatory screening resultsComp.Paw oedema thickness (mm)30 m (X ± SE)Oedema\
Inhibition (%)60 m (X ± SE)Oedema\
Inhibition (%)**Control**1.3 ± 0.05--1.5 ± 0.03--**17a**1.1 ± 0.0315.31.1 ± 0.0026.6**17b**1.2 ± 0.037.61.1 ± 0.0626.6**Nimesulide**1.1 ± 0.0515.31.1 ± 0.0026.6 Table 18Anti-inflammatory screening resultsComp.Paw oedema thickness (mm)120 m (X ± SE)Oedema\
Inhibition (%)180 m (X ± SE)Oedema\
Inhibition (%)**Control**1.7 ± 0.03--1.8 ± 0.03--**17a**1.1 ± 0.0341.11.0 ± 0.0344.4**17b**1.4 ± 0.0317.61.5 ± 0.0516.6**Nimesulide**1.0 ± 0.0041.11.1 ± 0.0044.4

El-Feky et al. designed novel fluorinated quinoline incorporated benzimidazoles and evaluated for their in vivo anti-inflammatory activity by carrageenin induced edema bioassay method in rats using celecoxib. Among them, compound **18a** demonstrated the highest anti-inflammatory activity and exhibited best binding profiles into the COX-2 binding site as compared to celecoxib. The significance result of the active compound is shown in Table [19](#Tab19){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"} \[[@CR31]\].Table 19Anti-inflammatory screening resultsCompAnti-inflammatory activityProtection at 50 mg/kg dose (%)**18a**55**Celecoxib**50

Gaba et al. reported phenylsulfonyl substituted benzimidazoles and evaluated in vivo for their anti-inflammatory activity (carrageenan-induced paw edema in rats) and analgesic activity (acetic acid-induced writhing test in mice), respectively. Among them, compounds **19a**, **19b**, **19c** and **19d** showed significant reduction in edema and compared to standard drug indomethacin and protection in the number of writhes produced by acetic acid, and comparable to the reference drug acetyl salicylic acid (Tables [20](#Tab20){ref-type="table"} and [21](#Tab21){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR7]\].Table 20Anti-inflammatory screening resultsComp.Edema at 3 h (%, mean ± SEM)Reduction in edema (%)**19a**68.66 ± 72.9931.34**19b**67.16 ± 73.0632.84**19c**65.67 ± 73.7834.33**19d**62.69 ± 73.2737.31**Control**100.00 ± 73.590.00**Indomethacin**52.23 ± 74.2747.76 Table 21Analgesic screening resultsComp.No. of writhes in 15 min (%, Mean ± SEM)Protection (%)**19a**32.33 ± 73.6254.03**19b**33.17 ± 73.3952.84**19c**32.67 ± 73.5753.55**19d**29.83 ± 72.4557.58**Control**70.33 ± 73.010.00**Acetyl salicylic acid**25.67 ± 71.45 63.51 Fig. 5Molecular structures of compounds (**19a**--**19d**, **20a**--**20b**, **21a**--**21c**, **22a**--**22b**, **23a**--**23d**)

Jesudason et al. reported a class of *N*-Mannich bases of benzimidazole compounds and screened for its analgesic activity by the acetic acid induced writhing method using Wistar albino mice and anti-inflammatory activity by the formalin-induced paw edema method on Wistar albino rats by plethysmography. In this series, compound **20a** exhibited similar results to paracetamol and compound **20b** showed more potent than diclofenac (Tables [22](#Tab22){ref-type="table"} and [23](#Tab23){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR32]\].Table 22Analgesic screening results and LD~50~Comp.Dose (mg/kg)% ProtectionLD~50~ (mg/kg)**20a**2032.21754047.49**Paracetamol**10047.76-- Table 23Anti-inflammatory screening resultsComp.Dose (mg/kg)% Reduction of edema30 min60 min90 min120 min**20b**4048565962**Diclofenac**5048656465

Mariappan et al. developed some 2-substituted benzimidazole molecules and screened for their in vivo anti-inflammatory and analgesic activities using pentazocine as standard. Among the synthesized derivatives, compounds **21a**, **21b**, **21c** showed significant analgesic and anti-inflammatory activity (Tables [24](#Tab24){ref-type="table"} and [25](#Tab25){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR33]\].Table 24Analgesic activities of benzimidazole compounds 21a-c via Tail-flick methodComp.(Mean ± SEM) tail withdrawing time in second0 h1 h2 h3 h4 h**Control (0.5% CMC)**1.56 ± 0.162.16 ± 0.162.33 ± 0.212.66 ± 0.212.82 ± 0.72**Pentazocine**2.16 ± 0.168.5 ± 0.3411.33 ± 0.2110.16 ± 0.3010.83 ± 0.30**21a**2.0 ± 0.253.0 ± 0.254.16 ± 0.3310.5 ± 0.229.83 ± 0.33**21b**2.0 ± 0.254.33 ± 0.213.73 ± 0.308.63 ± 0.2110.03 ± 0.30**21c**2.0 ± 0.256.51 ± 0.217.83 ± 0.309.73 ± 0.219.25 ± 0.30 Table 25Anti-inflammatory activities of benzimidazole compounds 21a-c by carrageenan-induced rat paws edema methodComp.(Mean ± SEM) tail withdrawing time in secondInhibition (%)0 h1 h2 h3 h4 h4 h**Control (0.5% CMC)**0.14 ± 0.010.23 ± 0.010.24 ± 0.020.25 ± 0.010.25 ± 0.01--**Pentazocine**0.14 ± 0.010.12 ± 0.010.12 ± 0.010.10 ± 0.010.09 ± 0.0164**21a**0.14 ± 0.020.12 ± 0.020.11 ± 0.010.11 ± 0.020.10 ± 0.0160**21b**0.15 ± 0.020.15 ± 0.010.13 ± 0.010.13 ± 0.010.10 ± 0.0160**21c**0.14 ± 0.010.13 ± 0.010.12 ± 0.010.10 ± 0.110.09 ± 0.0264

Paramashivappa et al. synthesized a class of substituted benzimidazoles and assessed for its human cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) enzyme inhibition activity in human whole blood assay using rofecoxib as reference. In this series, compound **22a** and **22b** were found as most active agents (Table [26](#Tab26){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR34]\].Table 26Inhibitory effect on COX-2 and COX-1 activity in human whole blood assayComp.COX-2 IC~50~ µMCOX-1 IC~50~ µMCOX-1/COX-2**22a**1384384**22b**1.06\> 500\> 470**Rofecoxib**0.05711.4200

Ravindernath et al. designed new benzo\[*d*\]imidazolyl tetrahydropyridine carboxylates and evaluated for their anti-inflammatory activity by the Carrageenan-induced paw edema test in rats using diclofenac sodium as a reference drug for comparison. All synthesized compounds (**23a**--**23d**) displayed appreciable activity. The significance results of the active compounds are shown in Table [27](#Tab27){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"} \[[@CR35]\].Table 27Anti-inflammatory screening resultsComp.Time1 h2 h3 h4 h**23a**0.78 ± 0.0221.45 ± 0.0570.5 ± 0.0270.08 ± 0.003**23b**0.55 ± 0.03891.583 ± 0.0450.616 ± 0.03150.3 ± 0.023**23c**0.64 ± 0.0111.4 ± 0.0380.31 ± 0.0240.31 ± 0.024**23d**0.82 ± 0.0301.76 ± 0.070.58 ± 0.030.1 ± 0.002**Control**0.90 ± 0.041.60 ± 0.0182.38 ± 0.023.25 ± 0.03**Diclofenac sodium**0.95 ± 0.031.72 ± 0.030.60 ± 0.030.60 ± 0.02

Sondhi et al. synthesized pyrimido\[1,6-*a*\]benzimidazoles and tested in vitro for their anti-inflammatory and analgesic activities using carrageenin induced paw oedema model. Among the synthesized compounds, compound **24a** (Fig. [6](#Fig6){ref-type="fig"}) displayed superior anti-inflammatory (46%) and mild analgesic activity (50%) using ibuprofen as standard (51% and 75%) \[[@CR28]\].Fig. 6Molecular structures of compounds (**24a**, **25a**--**25c**, **26a**, **27a**, **28a**, **29a**, **30a**--**30b**, **31a**--**31g**, **32a**--**32b**, **33a** and **34a**)

Sondhi et al. developed a class of benzimidazole acridine derivatives and tested for its anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activities using ibuprofen as standard. Among the series, compound **25a** displayed considerable activity against kinase while compounds **25b** and **25c** displayed significant anti-inflammatory and analgesic activities (Table [28](#Tab28){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR36]\].Table 28Anti-inflammatory, analgesic and kinase inhibition activitiesComp.Anti-inflammatory activity (%)Analgesic activity (%)Kinase IC~50~ (µM)CDK-1CDK-5GSK-3**25a**----7.44.642**25b**31.460------**25c**35.850------**Ibuprofen**38.850------

Vicini et al. synthesized benzimidazole tetrazolyl- and carboxyl-derivatives and screened for their anti-inflammatory and antipyretic activities in rat paw oedema and rat *Escherichia coli* derived LPS-induced pyrexia along with antinociceptive property examined in writhing and hot plate tests in mice. Among them, compound **26a** (1*H*-benzimidazol-2-yl) acetic acid showed central analgesic activity. The significance results of the active compounds are shown in Table [29](#Tab29){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"} \[[@CR37]\].Table 29Analgesic effect of compound 26a against acetic acid induced writhing in miceComp.ID~50~ (mg/kg os)Maximal inhibition % mean ± SEM**26a**\> 20042 ± 15**Acetaminophen**20890 ± 17

Wang et al. prepared a class of benzimidazole compounds and assessed for its in vitro H~1~ antihistamine activity. Among them, compound **27a** found to display excellent activity to reduce mast cell degranulation, moderate anti-PAF activity and decreased potency on hERG as compared to standard astermizole and desloratadine (Table [30](#Tab30){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR8]\].Table 30Antihistamine, receptor binding and anti-PAF activitiesComp.Anti H~1~ activity ileum IC~50~ (µmol/L)H~1~ receptor binding IC~50~ (µmol/L)PAF-induced platelet\
Aggregation IC~50~ (µmol/L)**27a**0.007940.00088178**Desloratadine**0.07210.00588130**Astermizole**0.04530.004ND

Yang et al. designed new benzimidazoles and then assessed for their in vitro phosphodiesterase 10A (PDE10A) inhibitor activity. From the newly developed compounds, compound **28a** (Fig. [6](#Fig6){ref-type="fig"}) showed good IC~50~ = 3.73 ± 0.60 nM along with selectivity (\> 1000-fold) for PDE10A \[[@CR38]\].

Antimalarial activity {#Sec7}
---------------------

Bandyopadhyay et al. synthesized new thiophosphorylated and phosphorylated benzimidazole derivatives and examined for their antimalarial activity toward *Aedes albopictus* and *Culex quinquefasciatus* for mosquito larvicidal properties at different concentration. Compound **29a** (Fig. [6](#Fig6){ref-type="fig"}) found most active toward *Ae. albopictus* (LC~50~---6.42 and 5.25 mg/L at 24 and 48 h) and *Cx. Quinquefasciatus* (LC~50~---7.01 and 3.88 mg/L) using temephos as positive control (2.85 ± 2.64, 2.8 ± 3.04 toward *Ae. Albopictus* and for *Cx. Quinquefasciatus* 3.04 ± 2.31, 3.55 ± 2.45) \[[@CR15]\].

Camacho et al. synthesized a class of *N*′-substituted-2-(5-nitrofuran or 5-nitrothiophen-2-yl)-3*H*-benzo\[*d*\]imidazole-5-carbohydrazides and investigated in vitro for its efficiency to inhibit *β*-hematin formation (I*β*HS), hemoglobin hydrolysis and then in vivo in rodent *Plasmodium berghei* for its antimalarial efficacy. Compounds **30a** and **30b** showed good antimalarial activity via inhibition of *β*-hematin formation and as proficient as chloroquine (Table [31](#Tab31){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR9]\].Table 31Antimalarial activity of benzimidazole derivatives (30a and 30b)Comp.I*β*HSIC~50~ (µM)IGP% PSD**30a**95.43 ± 0.588.4304.02 ± 0.4517 ± 1.26**30b**75.76 ± 0.9911.1014.08 ± 0.881.8 ± 0.4918.8 ± 2.05**Leupeptin**----91.62 ± 0.69----**Pepstatin**----95.45 ± 0.66----**Chloroquine**94.19 ± 0.36--24.12 ± 1.161.3 ± 0.3\> 30**Saline Solution**------21.8 ± 2.3111.66 ± 1.66

Divatia et al. synthesized novel thiosemicarbazones containing benzimidazole nucleus and evaluated for their in vitro antimalarial activity towards *P. falciparum* by minimum inhibitory concentration using chloroquine and quinine as standards. Among them, compounds **31a**, **31b**, **31c**, **31d**, **31e**, **31f** and **31g** showed excellent antimalarial activity. From structure activity relationship study it was observed that compounds having electron withdrawing groups (EWG) (*chloro*, *fluoro* and *iodo*) showed promising activity (Table [32](#Tab32){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR39]\].Table 32Antimalarial activity of benzimidazole derivatives 30a and 31 gComp.Minimum inhibitory concentration (IC~50~ µg/mL)**31a**0.023**31b**0.003**31c**0.012**31d**0.025**31e**0.005**31f**0.26**31** **g**0.15**Quinine**0.268**Chloroquine**0.020

Toro et al. reported ferrocenyl and cyrhetrenyl benzimidazoles and evaluated for their in vitro antimalarial activity against chloroquine susceptible-strain (3D7) and the chloroquine resistant-strain (W2) of *Plasmodium falciparum*. A better activity was observed for the compounds **32a--32b** (Fig. [6](#Fig6){ref-type="fig"}) (IC~50~ = 10.4--26.5 μM) than its ferrocenyl analog 1-Fe-(H, NO~2~) (IC~50~ = 23.9--48.0 μM) \[[@CR40]\].

Anti-mycobacterial/antitubercular activity {#Sec8}
------------------------------------------

Camacho et al. synthesized some novel *N*′-substituted-2-(5-nitrofuran or 5-nitrothiophen-2-yl)-3*H*-benzo\[*d*\]imidazole-5-carbohydrazide compounds and investigated for their antitubercular potency against multidrug resistant MDR-MTB and MTB H~37~Rv strains. Compounds **33a** (Fig. [6](#Fig6){ref-type="fig"}) exhibited good anti-mycobacterial activity (MIC = 12.5 µg/mL) against sensitive *M. tuberculosis* H~37~Rv and MDR-MTB (MIC = 6.25 µg/mL) strains and compared to isoniazid (MIC = 0.063 µg/mL) and rifampin (MIC = 32 µg/mL) \[[@CR9]\].

Gong et al. reported a new series of substituted benzimidazole derivatives and investigated for their antitubercular potency against *M. tuberculosis* in a replicating state (R-*Mtb*), a physiologically-induced non-replicating state (NR-*Mtb*). Among the synthesized derivatives, compound **34a** (Fig. [6](#Fig6){ref-type="fig"}) (NR-*Mtb*: MIC~90~ = 0.20 µg/mL; R-*Mtb*: MIC~90~ \< 0.049 µg/mL) \[[@CR16]\].

Desai et al. reported a class of benzimidazole containing 2-pyridones compounds and evaluated for its antimycobacterial potential towards *M. tuberculosis* H~37~Rv strain in Middlebrook 7H12 medium by microplate alamar blue assay (MABA) using isoniazid as a reference drug. In this series, compounds **35a**, **35b**, **35c**, **35d** and **35e** (Fig. [7](#Fig7){ref-type="fig"}) exhibited good activity with MIC values (2.76--20.4 µM) as compared to isoniazid with MIC value (0.24 µM) \[[@CR10]\].Fig. 7Molecular structures of compounds (**35a**--**35e**, **36a**--**36d**, **37a**, **38a**--**38g**)

Kalalbandi et al. developed a novel class of 1-\[(2*E*)-3-phenylprop-2-enoyl\]-1*H*-benzimidazoles and assessed for its antitubercular activity towards *M. tuberculosis* H~37~Rv by microplate alamar blue assay. Among them, compounds **36a**, **36b**, **36c** and **36d** (Fig. [7](#Fig7){ref-type="fig"}) (MIC = 3.12, 6.25, 3.12 and 1.6 µg/mL, respectively) showed excellent in vitro activity against H~37~Rv strain as compared to pyrazinamide, streptomycin and rifampicin having MIC = 3.12, 6.25 and 0.12 µg/mL, respectively \[[@CR41]\].

Park et al. synthesized some new 2,5,6-trisubstituted benzimidazoles and assessed for their antitubercular potential against drug sensitive *Mtb* H~37~Rv strain using microplate alamar blue assay. Compound **37a** (Fig. [7](#Fig7){ref-type="fig"}) displayed the best potency with the MIC value (0.63 µg/mL) against *Mtb* H~37~Rv \[[@CR42]\].

Ramprasad et al. synthesized some imidazo\[2,1-*b*\] \[[@CR1], [@CR3], [@CR4]\] thiadiazole-benzimidazole compounds and evaluated for their in vitro antituberculosis potency against *M. tuberculosis* H~37~Rv strain by agar dilution method using standard drugs ethambutol, isoniazid and pyrazinamide for comparison which showed the values in the range of 3.125--50.0 µg/mL. Among the synthesized compounds, compounds **38a**, **38b**, **38c**, **38d**, **38e**, **38f** and **38g** (Fig. [7](#Fig7){ref-type="fig"}) showed potent anti-tubercular activity with MIC value (3.125 µg/mL) and comparable to standard ethambutol (MIC = 3.13 µg/mL) \[[@CR43]\].

Ranjith et al. developed a class of positional isomers having benzimidazole moiety and evaluated for its antitubercular potency against *M. smegmatis* (MS), *M. tuberculosis* H~37~Rv (MTB), *M. fortuitum* (MF) and MDR-TB strains using isoniazid and rifampicin as standards. Among the synthesized derivatives, compounds **39a**, **39b** and **39c** displayed significant activity against *M. tuberculosis* H~37~Rv (Table [33](#Tab33){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR44]\].Table 33Antitubercular screening resultsComp.Screening results, MIC (µg/mL)MTBMSMFMDR-TB**39a**0.62510106.25**39b**0.6251.25106.25**39c**0.6251.25106.25**Isoniazid**0.75012.512.5**Rifampicin**0.51.51.525 Fig. 8Molecular structures of compounds (**39a**--**39c**, **40a**--**40e**, **41a**, **42a**--**42b**, **43a**--**43c**, **44a**--**44b**)

Shingalapur et al. synthesized some novel 5-(nitro/bromo)-styryl-2-benzimidazole compounds and evaluated for their in vitro anti-tubercular activity towards *M. tuberculosis* H37 Rv by alamar blue assay using streptomycin (100% inhibition) as reference. Among them, compounds **40a**, **40b**, **40c**, **40d** and **40e** showed significant antitubercular activity (Table [34](#Tab34){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR45]\].Table 34Antitubercular activity {MIC (µg/mL)}Comp.*M. tuberculosis* H37 Rv**40a**\> 7.25 (45)**40b**\> 7.25 (83)**40c**\> 7.25 (54)**40d**\> 7.25 (63)**40e**\> 7.25 (76)

Yoon et al. prepared some new benzimidazole derivatives and evaluated for their antimycobacterial potency against *M. tuberculosis* H37Rv strain using BacTiter-Glo™ microbial cell viability (BTG) assay using six standard drugs (rifampicin, cycloserine, pyrimethamine, isoniazid, amikacin and ethambutol). In this series, compound **41a** was found to be the highly potent agent as compared to standard drugs (Table [35](#Tab35){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR46]\].Table 35Antimycobacterial activity of benzimidazole derivative **41a**Comp.*M. tuberculosis* H37RvAlamar blueBTGIC~50~ (µM)IC~90~ (µM)MIC (µM)IC~50~ (µM)IC~90~ (µM)MIC (µM)**41a**16.1444.4610011.5216.5350**Amikacin**0.120.140.160.070.120.16**Cycloserine**24.7628.0110023.5526.38100**Ethambutol**3.45\> 200NA1.501.646.25**Isoniazid**0.19\> 5NA0.130.200.31**Pyrimethamine**25.0928.0010024.2746.37100**Rifampicin**0.020.020.160.020.030.04

Antiviral activity {#Sec9}
------------------

Cheng et al. synthesized some novel benzimidazoles and demonstrated for their antiviral activity against Coxsackie virus B~3~ in VERO cells. Among the synthesized derivatives, compounds **42a** and **42b** (Fig. [8](#Fig8){ref-type="fig"}) showed potent selective activity with IC~50~ values (1.43 and 0.54 µg/mL) as compared to ribavirin (RVB) with IC~50~ value and eminent selective index (411.7 µg/mL and \> 2.42) \[[@CR47]\].

Fonseca et al. synthesized benzimidazole compounds incorporated into a hydrophenanthrene and naphthalene skeleton and screened for their in vitro antiviral activity against several RNA and DNA viruses. Among them, compounds **43a**, **43b** and **43c** (Fig. [8](#Fig8){ref-type="fig"}) displayed good activity against VZV and CMV replication and comparable to that of acyclovir and ganciclovir (Table [36](#Tab36){ref-type="table"}) \[[@CR48]\].Table 36Antiviral screening results of the synthesized compounds **(43a-c)**Comp.Antiviral potency IC~50~ (µg/mL)CMVVZV**43a**\> 0.20.2--0.5**43b**1.1--3.20.6--2.8**43c**1.0--1.20.8--1.4**Acyclovir**--0.3--3.0**Ganciclovir**0.9--1.5--

Hwu et al. developed some new benzimidazole derivatives bearing coumarin ring and evaluated for their antiviral activity against the hepatitis C virus. Among the synthesized derivatives, compounds **44a** and **44b** (Fig. [8](#Fig8){ref-type="fig"}) were found to be most active and showed EC~50~ values (3.4 µM and 4.1 µM) \[[@CR49]\].

Li et al. synthesized a class of novel benzimidazoles and assessed for their hepatitis B virus inhibition activity. Among them, compounds **45a** and **45b** showed outstanding anti-HBV potency and comparable to lamivudine and adefovir (Table [37](#Tab37){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR50]\].Table 37Antiviral activity results of the synthesized compounds (**45a**--**45b**)Comp.IC~50~ (µM)CC~50~ (µM)SI**45a**0.70192274**45b**0.7086123**Lamivudine**0.38\> 1000\> 2632**Adefovir**1.75734 Fig. 9Molecular structures of compounds (**45a**--**45b**, **46a**, **47a**, **48a**--**48b**, **49a**, **50a**--**50b**, **51a**--**51b**, **52a**, **53a**--**53b**, **54a**--**54b**)

Luo et al. developed few novel benzimidazole compounds and evaluated for their anti-hepatitis B virus (HBV) activity and cytotoxicity in HepG 2.2.15 cells. In this study, compound **46a** showed significant antiviral activity using lamivudine as reference (Table [38](#Tab38){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR51]\].Table 38Antiviral activity results of the synthesized compounds **46a**Comp.IC~50~ (µM)CC~50~ (µM)SI**46a**\< 0.4133.381.2**Lamivudine**50.163.13

Miller et al. designed a series of *N*-substituted benzimidazoles as CXCR4 antagonists. In this series, compound **47a** (Fig. [9](#Fig9){ref-type="fig"}) exhibited promising antiviral activity having IC~50~ of 2 nM, a 1000-fold cytotoxicity window and a twofold protein shift. A modification in side chain and stereochemical optimization led to significantly enhancement in potency and protein shift to afford compounds with low nanomolar anti-HIV activity \[[@CR52]\].

Monforte et al. synthesized some novel *N*~1~-aryl-2-arylthioacetamido-benzimidazoles and screened for their human immunodeficiency virus type-1 (HIV-1) inhibitor activity. In this series, compounds **48a** and **48b** were found as the most active compounds with no toxicity (Table [39](#Tab39){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR11]\].Table 39Anti-RT and anti-HIV-1 activities, cytotoxicity and selectivity index in MT-4 cellsComp.IC~50~ (µM)EC~50~ (µM)CC~50~ (µM)SI**48a**0.12 ± 0.0350.04 ± 0.01\> 221.59\> 5540**48b**0.18 ± 0.0180.06 ± 0.02≥ 235.64≥ 3927**Nevirapine**2.55 ± 0.930.19 ± 0.06\> 15.02\> 79**Efavirenz**0.032 ± 0.0090.006 ± 0.0001\> 1056\> 6.34

Starcevic et al. synthesized 2-substituted-5-amidino-benzimidazoles and assessed for their in vitro inhibitory activity against GMK cell line and HeLa cell line by MTT assay. From this series, compound **49a** showed prominent activity against all four types of viruses with no cytotoxicity (Table [40](#Tab40){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR12]\].Table 40Antiviral activity EC~50~ (µM)Comp.HeLaGMKAdenovirus 5Herpesvirus 1Coxsackievirus B5Echovirus 7**49a**5.9303.55

Zhang et al. reported some new benzimidazole derivatives and screened for their anti-Coxsackie virus B3 (CVB3) activity in VERO cells. In this series, compounds **50a** and **50b** (Fig. [9](#Fig9){ref-type="fig"}) exhibited better inhibitory activity with IC~50~ values (5.30 and 1.06 µg/mL) together with good selective indexes (12.1 and 7.5) than those of ribavirin (RBV) with IC~50~ value 353.33 \[[@CR53]\].

Anticancer activity {#Sec10}
-------------------

In this study, Tahlan et al. developed a new class of benzimidazole benzamide compounds and demonstrated for its anticancer activity against cancer cell line (HCT116) by SRB method and compared to standard drugs (5-fluorouracil). From the synthesized derivatives, compound **51a** and **51b** (Fig. [9](#Fig9){ref-type="fig"}) showed the significant anticancer activity (Table [41](#Tab41){ref-type="table"}) \[[@CR3]\].Table 41Anticancer activity results of synthesized compounds (**51a** and **51b**)Comp.Cancer cell line (IC~50~ = μM)HCT116**51a**5.85**51b**4.53**5-Fluorouracil**9.99

Designed and synthesized a novel series of benzimidazole derivatives by Tahlan et al. and evaluated for its anticancer potency towards cancer cell line (HCT116) by SRB assay. In this series, compound **52a** (Fig. [9](#Fig9){ref-type="fig"}) was found to be most promising anticancer compound. The significant result of the most active compound is shown in Table [42](#Tab42){ref-type="table"} \[[@CR2]\].Table 42Anticancer activity results of synthesized compound (**52a**)Comp.Cancer cell line (IC~50~ = μM)HCT116**52a**4.12**5-Fluorouracil**7.69

Antimicrobial activity {#Sec11}
----------------------

Novel class of benzimidazole Schiff base derivatives has been synthesized by Tahlan et al. and evaluated for their antimicrobial activity against Gram positive and Gram negative bacterial and fungal species by tube dilution method. In this series, compounds **53a** and **53b** (Fig. [9](#Fig9){ref-type="fig"}) displayed potent antifungal activity against *A. niger* and *C. albicans*. The significant result of the active compounds is shown in Table [43](#Tab43){ref-type="table"} \[[@CR54]\].Table 43Antimicrobial results of compounds (**53a**--**53b**)Comp.Microbial strains (MIC = µM/mL)Bacterial strainsFungal strains*S. aureusE. coliB. subtilisP. aeruginosaS. entericaC. albicansA. niger***53a**9.629.622.412.414.812.411.20**53b**5.822.915.825.825.821.462.91**Cefadroxil**1.721.721.721.721.72----**Fluconazole**----------2.042.04

Tahlan et al. synthesized a class of benzimidazole Schiff base derivatives and screened for its antimicrobial activity toward selected microbial species. From the series compounds **54a** and **54b** (Fig. [9](#Fig9){ref-type="fig"}) exhibited promising antimicrobial activity towards bacterial and fungal species. The significant result of the active compounds is shown in Table [44](#Tab44){ref-type="table"} \[[@CR55]\].Table 44Antimicrobial results of compounds (**54a**--**54b**)Comp.Microbial strains (MIC = µM/mL)Bacterial speciesFungal species*B. subtilisP. aeruginosaE. coliS. typhiK. pneumoniaeC. albicansA. niger***54a**1.281.281.282.555.115.112.55**54b**0.680.682.722.725.445.442.72**Cefadroxil**1.733.463.460.863.46----**Fluconazole**----------4.084.08

Conclusion {#Sec12}
==========

The present review based on reported heterocyclic benzimidazole derivatives which displayed the significant biological potentials in medicinal chemistry. Benzimidazole moiety is the key building block for several heterocyclic scaffolds that play central role in the biologically functioning of essential molecules and are surprisingly effective with their restraint movement and favorable selectiveness. The present review article is based on various reported pharmacological activities of heterocyclic 1*H*-benzimidazole derivatives. The review article shows the pharmacological activities of the reported synthesized benzimidazole derivatives in medicinal field. We hope this paper may be helpful in the development of new derivatives of benzimidazole based on medicinal chemistry and as well as designing of new drug molecule in future.

AChE

:   acetylcholinesterase

AD

:   Alzheimer's disease

TB

:   tuberculosis

*M. tuberculosis*

:   *Mycobacterium tuberculosis*

GI

:   *Giardia intestinalis*

TV

:   *Trichomonas vaginalis*

EH

:   *Entamoeba histolytica*

LM

:   *Leishmania mexicana*

ABZ

:   albendazole

SI

:   selectivity index

TS

:   *Trichinella spiralis*

TBZ

:   triclabendazole

MBZ

:   mebendazole

EWG

:   electron withdrawing groups

VZV

:   varicella-zoster virus

CMV

:   cytomegalovirus

WHO

:   World Health Organization

CRC

:   colorectal tumour

CSC

:   cancer stem cell

CDK

:   cyclin-dependent kinase
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